ARQT - Arcutis Biotherapeutics GAAP EPS of -$0.32 beats by $0.41 revenue of $49.56M
2024-05-14 16:22:07 ET
More on Arcutis Biotherapeutics
- Arcutis Biotherapeutics: Betting Big On Zoryve
- Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript
- Arcutis announces pricing of $150 million public offering
- Arcutis licenses Japanese rights for Zoryve to Sato Pharmaceutical
- Seeking Alpha’s Quant Rating on Arcutis Biotherapeutics